Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Ontology highlight
SUBMITTER: Popat R
PROVIDER: S-EPMC11494064 | biostudies-literature | 2024 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA